Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Jennifer Kiser to Drug Therapy, Combination

This is a "connection" page, showing publications Jennifer Kiser has written about Drug Therapy, Combination.

 
Connection Strength
 
 
 
0.905
 
  1. MacBrayne CE, Castillo-Mancilla J, Burton JR, MaWhinney S, Wagner CB, Micke K, Fey J, Huntley RT, Larson B, Bushman LR, Kiser JJ. Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers. J Antimicrob Chemother. 2018 Jan 01; 73(1):156-159.
    View in: PubMed
    Score: 0.121
  2. Kiser JJ, Lu D, Rosenkranz SL, Morse GD, DiFrancesco R, Sherman KE, Butt AA. Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s. Drugs R D. 2017 Dec; 17(4):557-567.
    View in: PubMed
    Score: 0.120
  3. Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions. World J Gastroenterol. 2017 Mar 07; 23(9):1618-1626.
    View in: PubMed
    Score: 0.114
  4. Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013 Oct; 10(10):596-606.
    View in: PubMed
    Score: 0.088
  5. Hammond KP, Wolfe P, Burton JR, Predhomme JA, Ellis CM, Ray ML, Bushman LR, Kiser JJ. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013 Jan 01; 62(1):67-73.
    View in: PubMed
    Score: 0.085
  6. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013; 53:427-49.
    View in: PubMed
    Score: 0.084
  7. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology. 2012 May; 55(5):1620-8.
    View in: PubMed
    Score: 0.081
  8. Kiser JJ, Rutstein RM, Samson P, Graham B, Aldrovandi G, Mofenson LM, Smith E, Schnittman S, Fenton T, Brundage RC, Fletcher CV. Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. AIDS. 2011 Jul 31; 25(12):1489-96.
    View in: PubMed
    Score: 0.077
  9. Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2008 Feb; 52(2):631-7.
    View in: PubMed
    Score: 0.060
  10. Kakuda TN, Kiser JJ. 7th International Workshop on Clinical Pharmacology of HIV Therapy 20-22 April 2006, Lisbon, Portugal. Expert Opin Pharmacother. 2006 Aug; 7(11):1519-33.
    View in: PubMed
    Score: 0.055
  11. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol. 2012; 2012:137192.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)